To the relevant abstract in JapaneseCurrent status of natural product screening programs in Japan
Toru Okuda
Programme and Abstracts of Ninth International Congress for Culture Collections, Brisbane, Australia. 23-38 July, 2000. 61p.
The expectation toward fungal metabolites was tremendous since blockbuster drugs such as mevalotin and cyclosporine were launched more than a decade ago. During these years, meanwhile, technologies for drug discovery process have been highly advanced and diversified. Pharmaceutical industries are keeping up with heavy competition with high-throughput screening (HTS), combinatorial chemistry and genomics. The better-faster-cheaper strategy tends to drive out the natural products screening (NPS) programs, which take time and cost much. Recently, we took a survey of the NPS activities by sending questionnaires to various organizations mainly in Japan. Seventy-three percent of them are conducting NPS. However, they are facing difficulties including pure technological problems to cope with HTS and more political issues such as Conventions on Biological Diversity. I will discuss trends and future in the NPS programs. I will also touch on the possible roles of culture collections in the future based on our expectations towards Japanfs biological resource center.
Go back to the list of publication
To the relevant abstract in Japanese
Last update on
2001/07/19
Copyright © TorulopsisOktavianus
reprint request to Toru Okuda